Alphamab Oncology stock analysis
Want to see HK:9966 full AI Analyst Report?
Alphamab Oncology (9966) Stock Price & Analysis
9966 Stock Chart & Stats
- Day’s Range
- HKD 5.98 - HKD 6.22
- 52-Week Range
- HKD 5.87 - HKD 12.20
- Previous Close
- HKD 6.25
- Volume
- N/A
- Average Volume (3M)
- 1.16M
- Market Cap
- HKD 6.09B
- Enterprise Value
- HKD 5.37B
- Total Cash (Recent Filing)
- HKD 1.43B
- Total Debt (Recent Filing)
- HKD 268.36M
- Price to Earnings (P/E)
- ―
- Beta
- 0.76
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin
A gross margin of about 77% indicates that Alphamab retains substantial value after direct product costs. If maintained as oncology products scale, this provides room to fund research, commercialization, and operating expenses while supporting potential long-term operating leverage.
Conservative Leverage
Very low debt relative to equity gives Alphamab greater financial flexibility than a heavily leveraged biotech. The conservative capital structure can help the company continue developing oncology programs and absorb business volatility without relying as heavily on debt financing.
Established Asset Base
A sizable equity base provides an important financial foundation for a research-led oncology company with long development cycles. It supports the existing asset base and gives management more capacity to allocate resources across development and commercialization priorities.
Bears Say
Revenue Contraction
The sharp 2025 revenue decline signals that recent commercial or partnered income has not been consistently sustained. Continued contraction would reduce resources available for research and commercialization, making future growth more dependent on successful product execution.
Volatile Profitability
A return to significant losses after a profitable year shows that Alphamab’s earnings base remains unstable. Inconsistent operating profitability can limit internally funded investment, complicate planning, and increase sensitivity to delays or weaker performance across oncology programs.
Renewed Cash Burn
The shift from positive operating and free cash flow in 2024 to substantial cash burn in 2025 raises funding sensitivity if losses persist. Ongoing negative cash generation could constrain development spending or require additional financing over the next several quarters.
Alphamab Oncology News
Alphamab’s Anbenitamab Delivers Strong Phase III Results in HER2-Positive Breast Cancer
Alphamab Oncology ( ($HK:9966) ) just unveiled an announcement. Alphamab Oncology reported significant phase III clinical data for its HER2-targeting bispecific antibody Anbenitamab (KN026), used in combination with HB1801 as
Alphamab Oncology’s JSKN033 Shows Strong Cervical Cancer Data, Backing Phase III Push
Alphamab Oncology ( ($HK:9966) ) has shared an update. Alphamab Oncology, a China-based biopharmaceutical firm specializing in advanced antibody-based cancer therapies, is developing a broad pipeline of ADCs, monoclonal and
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
What is Alphamab Oncology’s market cap?
When is Alphamab Oncology’s upcoming earnings report date?
How were Alphamab Oncology’s earnings last quarter?
Is Alphamab Oncology overvalued?
Does Alphamab Oncology pay dividends?
What is Alphamab Oncology’s EPS estimate?
How many shares outstanding does Alphamab Oncology have?
What happened to Alphamab Oncology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alphamab Oncology?
What is the TipRanks Smart Score and how is it calculated?
Alphamab Oncology Stock Smart Score
Company Description
Alphamab Oncology
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ting Xu
- Employees
- 515
- Website
- www.alphamabonc.com
- Address
- No. 175 Fangzhou Road, Suzhou, JS, 215127, CN
Alphamab Oncology (9966) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |
